Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

GeneDx Holdings (WGS) EBIT (2020 - 2026)

GeneDx Holdings has reported EBIT over the past 7 years, most recently at -$57.5 million for Q1 2026.

  • Quarterly EBIT fell 1162.82% to -$57.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$66.0 million through Mar 2026, down 367.93% year-over-year, with the annual reading at -$13.1 million for FY2025, 43.67% up from the prior year.
  • EBIT was -$57.5 million for Q1 2026 at GeneDx Holdings, down from -$14.2 million in the prior quarter.
  • Over five years, EBIT peaked at $9.0 million in Q2 2025 and troughed at -$324.9 million in Q4 2022.
  • The 5-year median for EBIT is -$25.6 million (2023), against an average of -$55.4 million.
  • Year-over-year, EBIT surged 184.7% in 2025 and then tumbled 1162.82% in 2026.
  • A 5-year view of EBIT shows it stood at -$324.9 million in 2022, then soared by 92.11% to -$25.6 million in 2023, then skyrocketed by 134.34% to $8.8 million in 2024, then plummeted by 261.65% to -$14.2 million in 2025, then crashed by 303.73% to -$57.5 million in 2026.
  • Per Business Quant, the three most recent readings for WGS's EBIT are -$57.5 million (Q1 2026), -$14.2 million (Q4 2025), and -$3.3 million (Q3 2025).